AMAG Pharmaceuticals, Inc. provides unaudited earnings guidance for the fourth quarter and full year of 2017 and 2018. For the quarter, the company expects total GAAP revenue to be between $155 million and $162 million, representing approximately 5% growth over the same period in 2016. This includes Makena net product sales of between $97 million and $102 million, Feraheme injection and MuGard net product sales of between $26 million and $28 million, Intrarosa net product sales of approximately $2 million, and Cord Blood Registry service revenue of approximately $30 million. The company expects total non-GAAP revenue to be between $156 million and $163 million, which reflects a $1.4 million purchase accounting adjustment related to CBR deferred revenue. An operating loss of between $6 million and $16 million and adjusted EBITDA of between $58 million and $68 million. For the full year 2017, the company expects 2017 total GAAP revenue to be between $607 million and $614 million, representing 15% growth over 2016. This includes Makena net product sales of between $385 million and $390 million, Feraheme and MuGard net product sales of between $106 million and $108 million, Intrarosa net product sales of approximately $2 million, and CBR service revenue of approximately $114 million. The company expects total non-GAAP revenue to be between $613 million and $620 million, which reflects a $5.5 million purchase accounting adjustment related to CBR deferred revenue. The company expects an operating loss of between $292 million and $302 million (due primarily to a third quarter non-cash accounting charge) and adjusted EBITDA of between $220 million and $230 million, the higher end of the guidance range. For the year 2018, the company expects total GAAP revenue to be between $500 million and $560 million, operating loss of between $147 million and $117 million, Non-GAAP revenue to be between $500 million and $560 million and Non-GAAP Adjusted EBITDA to be between $100 million and $130 million.